Cabaletta Bio Inc Cash Flow Conversion Efficiency
Cabaletta Bio Inc cash flow conversion efficiency. Based on the latest financial reports, Cabaletta Bio Inc (CABA) has a cash flow conversion efficiency ratio of -0.197x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-41.51 Million) by net assets ($210.59 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Cabaletta Bio Inc (2017–2025)
Cash flow conversion efficiency of Cabaletta Bio Inc from 2017 to 2025. This chart illustrates how Cabaletta Bio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Cabaletta Bio Inc for real-time trading data and today's change.
Cabaletta Bio Inc Cash Flow Conversion Ratio Explained
Cabaletta Bio Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Cabaletta Bio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cabaletta Bio Inc ranked by their cash flow conversion efficiency. Also see Cabaletta Bio Inc market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jena Acquisition Corporation II
NYSE:JENA
|
-0.001x |
|
EGing Photovoltaic Technology Co Ltd
SHG:600537
|
-0.135x |
|
Yunnan Bowin Technology Industry Co Ltd
SHG:600883
|
-0.001x |
|
GDI Property Group
AU:GDI
|
0.019x |
|
BRT Realty Trust
NYSE:BRT
|
0.040x |
|
Singaraja Putra
JK:SINI
|
0.040x |
|
Cogelec SA
PA:ALLEC
|
0.282x |
|
Guangzhou LBP Medicine Science & Technology Co Ltd
SHG:688393
|
0.024x |
Annual Cash Flow Conversion Efficiency for Cabaletta Bio Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Cabaletta Bio Inc from 2017 to 2025. Review Cabaletta Bio Inc financial flexibility index to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $112.05 Million | $-131.08 Million | -1.170x | -102.00% |
| 2024-12-31 | $152.34 Million | $-88.22 Million | -0.579x | -155.45% |
| 2023-12-31 | $236.20 Million | $-53.55 Million | -0.227x | +48.91% |
| 2022-12-31 | $104.52 Million | $-46.38 Million | -0.444x | -53.46% |
| 2021-12-31 | $117.96 Million | $-34.11 Million | -0.289x | -18.33% |
| 2020-12-31 | $109.54 Million | $-26.77 Million | -0.244x | -110.67% |
| 2019-12-31 | $138.32 Million | $-16.05 Million | -0.116x | -126.60% |
| 2018-12-31 | $-10.69 Million | $-4.66 Million | 0.436x | -97.67% |
| 2017-12-31 | $-249.00K | $-4.66 Million | 18.719x | -- |
About Cabaletta Bio Inc
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company's lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase synd… Read more